Drugs and Diagnostics for Hematological Disorders: Global Markets
NEW YORK, March 12, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Drugs and Diagnostics for Hematological Disorders: Global Markets
http://www.reportlinker.com/p01119541/Drugs-and-Diagnostics-for-Hematological-Disorders-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology
INTRODUCTION
STUDY GOALS AND OBJECTIVES This report "PHM116A Hematological Disorders: Drug Technologies, Diagnostics and Global Markets" provides an overview of the current and potential global market for hematological disorders, treatments and testing technologies. The key objective is to present a comprehensive analysis of the current state of hematological disorders and blood cancers, therapy and technology, and utilization of the various therapeutic and diagnostic modalities to prevent and treat these disorders. The report's focus is on hematological disorder treatment strategies such as hematological therapeutics and drugs, chemotherapy, radiotherapy and immunotherapy, and other treatment modalities and testing and screening methods. The report also includes an overview on hematological disorders and staging, diagnostic tests and technologies. Important trends in the field of hematological disorders and cancer research, new developments, and sales forecasts by treatment and screening categories from 2012 through 2017 are provided in this report. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the hematological disorders and blood cancer market.REASONS FOR DOING THIS STUDY This study was conducted to provide detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. There is an increasing need for new and innovative technologies. This industry is experiencing tremendous growth. Many diseases discussed in this report are global issues, and a need exists for newer diagnostic and treatment strategies. Some of these ailments affect children and the elderly. This study looks at most types of diagnostic and treatment strategies for the clinical management of hematological disorders and blood cancers.
This BCC market research report will increase the awareness of current and emerging drugs and technologies for hematological disorders and blood cancers, including hematological disorder therapeutics, chemotherapy, radiation therapy, surgical therapy, immunotherapy and also nutrition therapy.
INTENDED AUDIENCE
This report is an exhaustive study on the global hematological disorders and blood cancer market, with important statistics and analysis on existing drugs and diagnostic technologies, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in hematological disorders and blood cancer prevention and treatment strategies from the point of view of manufacturers, product suppliers, healthcare providers, and consumers of hematological disorder and cancer products and services. This study will be of interest largely to the pharmaceutical and biotechnology industries, as well as clinics, hospitals and research institutes. This report may also prove crucial for investment firms in the concerned sector. This report shows tests currently being used for hematological disorders and cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies. The report provides market data for 2010 to 2017 and also covers commercial prospects for hematological disorders and cancer diagnostic assays, current tests in use and their future.
SCOPE OF THE STUDY
The scope of this study is testing, screening technology and also therapeutics markets for hematological disorders and blood cancers. The report also includes the regulatory environment, current technologies, new technologies, hematological disorders and cancer incidence, market projections and market share, along with latest trends and new developments.
METHODOLOGY
Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, industry news and developments, and paid and free databases. The base year of the report is 2012, with forecast data provided through 2017. Historical, base year and forecast data are provided for each market segment of this report. The report provides a comprehensive review of prostate cancer, incidence and development of the disease, drugs currently being used and diagnostic technologies. The report also reviews technological developments, product innovations/introductions and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D and current product growth. Forecasts and projections were based on estimates such as the current trends, potential users, mergers and acquisitions, and market trends.
A comprehensive and exhaustive search of the literature on hematological disorders and blood cancers, assay development and already-marketed products, global incidence and latest drug developments was conducted. These secondary sources included scientific journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academics, technology and consulting companies.
INFORMATION SOURCES Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products, such as the pharmaceutical and biotechnical industries and research institutes. Data were gathered from various industry sources. BCC spoke with officials within the industry and consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.ABOUT THE AUTHOR Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including IND enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 1
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THIS STUDY 1
INTENDED AUDIENCE 1
SCOPE OF THE STUDY 2
METHODOLOGY 2
INFORMATION SOURCES 2
ABOUT THE AUTHOR 3
RELATED BCC REPORTS 3
BCC ON-LINE SERVICES 3
DISCLAIMER 3
CHAPTER 2 SUMMARY 5
SUMMARY TABLE HEMATOLOGICAL DISORDERS DRUGS AND DIAGNOSTICS:
GLOBAL MARKETS, THROUGH 2017 ($ MILLIONS) 6
SUMMARY FIGURE HEMATOLOGICAL DISORDERS DRUGS AND
DIAGNOSTICS: GLOBAL MARKETS, 2010-2017 ($ MILLIONS) 6
CHAPTER 3 OVERVIEW 9
TABLE 1 KEY BLOOD DISORDERS 9
TABLE 2 MALIGNANT BLOOD DISORDERS 10
TABLE 3 NON-MALIGNANT BLOOD DISORDERS 10
BLOOD DISEASES 11
TABLE 4 TYPE OF BLOOD CELLS AND FUNCTIONS 11
TABLE 5 BLOOD CELLS AND FUNCTION 12
BLOOD DISORDERS 12
ANEMIA 12
Types of Anemia 13
TABLE 6 THREE MAJOR TYPES OF ANEMIA 13
TABLE 7 ANEMIA: MAJOR CATEGORIES 14
Symptoms 14
TABLE 8 SYMPTOMS OF ANEMIA 15
TABLE 9 TYPES OF ANEMIA 16
MEGALOBLASTIC ANEMIAS 16
Cobalamin Deficiency 17
TABLE 10 DRUGS THAT CAN CAUSE COBALAMIN DEFICIENCY 18
Folate Deficiency 18
TABLE 11 DRUGS: CAUSE OF FOLATE DEFICIENCY 19
DISGNOSTIC TESTS 19
Schilling Test 19
Serum Ferritin and Iron Studies 20
Other Tests 20
TREATMENT 20
HEMOGLOBIN DISORDERS 21
THALASSEMIA 21
SICKLE-CELL ANEMIA 21
TABLE 12 KEY FACTS 22
Causes 22
World Health Organization's Resolutions 23
HEMOLYTIC ANEMIA 23
TABLE 13 LAB TESTS FOR ANEMIA 23
Treatment 24
Anemia Medications 24
HEMOSTASIS 25
HEMOSTASIS: STEPS OF MECHANISM 25
TABLE 14 HEMOSTASIS: THREE MAJOR STEPS 26
TYPES OF HEMOSTASIS 26
Hemostasis in Emergency Medicine 26
ARTIFICIAL HEMOSTASIS 27
TABLE 15 DRUGS THAT EFFECT ACTIVITY OF PLATELETS 28
TABLE 16 ANTICOAGULANTS THAT ACT ON THROMBIN 28
BLEEDING DISORDERS 29
TABLE 17 BLEEDING DISORDERS 29
TABLE 18 BLEEDING DISORDERS: SYMPTOMS 30
TABLE 19 SIGNS AND TESTS 30
HEMOPHILIA 30
TABLE 20 KEY CHARACTERISTICS: HEMOPHILIA 31
CLASSIFICATION 31
HISTORICAL BACKGROUND 32
The Clotting Cascade 32
Hemorrhage 33
Natural Inhibitors 33
ACQUIRED HEMOPHILIA 34
FORMS OF HEMOPHILIA 34
Symptoms and Complications 35
Diagnosis 35
Genetic Testing 36
Treatment 36
TABLE 21 FVIII INHIBITORS 39
TABLE 22 MEDICATIONS FOR TREATING HEMOPHILIA 40
Factor VIII Products 40
TABLE 23 FACTOR VIII PRODUCTS 41
Antifibrinolytics 41
TABLE 24 ANTIFIBRINOLYTICS 41
Antihemophilic Agents 41
TABLE 25 ANTIHEMOPHILIC AGENTS 42
Coagulation Factor VIIa, Recombinants 42
Factor VIIa, Recombinant (NovoSeven) 42
Monoclonal Antibodies 42
Rituximab (Rituxan) 43
VON WILLEBRAND DISEASE 43
Symptoms and Diagnosis 43
Treatment 43
THROMBOPHILIA 44
Diagnosis and Treatment 44
THROMBOSIS 45
TABLE 26 FORMATION OF THROMBUS 46
DEEP VEIN THROMBOSIS AND TREATMENT 46
Heparin 46
Warfarin 47
SUPERFICIAL THROMBOPHLEBITIS 47
DEEP VENOUS THROMBOSIS 47
Tests 47
Treatment 48
Surgery 48
HEREDITARY HEMORRHAGIC TELANGIECTASIA 48
ERYTHROCYTOSIS 49
ABSOLUTE POLYCYTHEMIA 49
Primary Polycythemia 49
Secondary Polycythemia 50
Chuvash Polycythemia 50
Relative Polycythemia 51
WHITE BLOOD CELL DISORDERS 51
TREATMENT 51
NEUTROPENIA 52
Causes 52
TABLE 27 CAUSES FOR NEUTROPENIA 53
Symptoms and Diagnosis 53
Treatment 53
NEUTROPHILIA 54
BLOOD DISORDERS AFFECTING PLATELETS 55
TABLE 28 WHITE BLOOD CELLS AND DISEASES 55
THROMBOCYTOPENIA 55
Treatment 56
LYMPHOCYTOPENIA 56
Treatment 56
LYMPHOCYTIC LEUKOCYTOSIS 56
MONOCYTOSIS 57
THROMBOCYTHEMIA AND THROMBOCYTOSIS 57
Primary Thrombocythemia 57
Secondary Thrombocytosis 57
TABLE 29 CAUSE OF SECONDARY THROMBOCYTOSIS 58
Symptoms 59
TABLE 30 DIAGNOSTIC TESTS 59
Treatment 60
TABLE 31 MEDICINES FOR THROMBOCYTHEMIA 60
THROMBOCYTOPENIA 61
Causes 61
TABLE 32 CAUSES OF THROMBOCYTOPENIA 61
RARE CONDITIONS THAT CAUSE BLOOD CLOTS 62
Signs and Symptoms 63
TABLE 33 SIGNS OF EXTERNAL BLEEDING 63
Tests 63
Treatment 63
SEVERE THROMBOCYTOPENIA 63
EOSINOPHILS AND DISORDERS 64
TABLE 34 COMMON DRUGS TO TREAT EOSINOPHILIA 64
BASOPHILS AND DISORDERS 65
PLASMA CELL DISORDERS 65
CHAPTER 4 HEMATOLOGICAL CANCERS 67
TABLE 35 HEMATOLOGICAL CANCERS (BLOOD CANCERS) 67
CLASSIC CLASSIFICATION 68
TABLE 36 RELATIVE OCCURRENCE OF HEMATOLOGICAL MALIGNANCIES IN
THE U.S. (%) 68
TABLE 37 TYPES OF HEMATOLOGICAL CANCERS 69
ACUTE MYELOID LEUKEMIA 70
CHRONIC MYELOID LEUKEMIA 70
ACUTE LYMPHOCYTIC LEUKEMIA 71
CHRONIC LYMPHOCYTIC LEUKEMIA 71
HODGKIN LYMPHOMA 71
NON-HODGKIN LYMPHOMA 72
TREATMENT AND SIDE EFFECTS 72
MULTIPLE MYELOMA 72
MYELODYSPLASTIC SYNDROME 72
DIAGNOSIS 73
TABLE 38 FDA APPROVED DRUGS FOR HEMATOLOGY, 2012 73
TABLE 39 NEW HEMATOLOGY DRUG APPROVALS, 2012 73
TABLE 40 FDA APPROVED DRUGS FOR HEMATOLOGY, 2011 74
TABLE 41 APPROVED FDA DRUGS FOR HEMATOLOGICAL DISEASES,
1996-2010 75
CHAPTER 5 HEMATOLOGICAL CANCERS: LEUKEMIA 79
LYMPHOCYTIC LEUKEMIAS 80
MYELOGENOUS LEUKEMIAS 80
TABLE 42 TYPES OF LEUKEMIA 80
TABLE 43 TYPES OF LEUKEMIA AND KEY FEATURES 81
SYMPTOMS 82
CAUSES 83
DIAGNOSIS 84
TESTS 84
TABLE 44 DIAGNOSTIC EXAMS FOR LEUKEMIA 85
COMPLETE BLOOD COUNT 85
WHITE CELL DIFFERENTIAL 85
BLOOD SMEAR 85
TABLE 45 ADDITIONAL TESTS 86
FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 86
FLOW CYTOMETRY 86
Immunophenotyping 87
KARYOTYPE TEST 87
POLYMERASE CHAIN REACTION 87
BONE MARROW ASPIRATION/BIOPSY 87
SPINAL TAP (LUMBAR PUNCTURE) AND CEREBROSPINAL FLUID
(CSF) ANALYSIS 88
IMMUNOPHENOTYPING OR PHENOTYPING BY FLOW CYTOMETRY 88
CYTOGENETICS AND FLUORESCENT IN SITU HYBRIDIZATION (FISH) 88
POLYMERASE CHAIN REACTION (PCR) 88
TABLE 46 PCR TESTS 89
NON-LABORATORY TESTS 89
TABLE 47 NON-LABORATORY TESTS 89
TREATMENT 89
TABLE 48 COMMON TREATMENTS USED TO FIGHT LEUKEMIA 90
TABLE 49 NEWER CLASSES OF DRUGS 91
DRUG THERAPIES FOR BLOOD CANCERS 91
TABLE 50 ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) TREATMENT 93
TABLE 51 DRUGS APPROVED FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 94
TABLE 52 DRUGS APPROVED FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 95
TABLE 53 DRUGS APPROVED FOR ACUTE MYELOID LEUKEMIA (AML) 96
TABLE 54 DRUGS APPROVED FOR CHRONIC MYELOGENOUS LEUKEMIA
(CML) 97
HAIRY CELL LEUKEMIA: TREATMENT 97
T-CELL PROLYMPHOCYTIC LEUKEMIA 98
TABLE 55 T-CELL PROLYMPHOCYTIC LEUKEMIA: TREATMENT PLAN 98
JUVENILE MYELOMONOCYTIC LEUKEMIA 98
STAGES OF LEUKEMIA 99
TABLE 56 FACTORS AFFECTING LEUKEMIA STAGING AND PROGNOSIS 99
TREATMENTS AND DRUGS 99
STEM CELL TRANSPLANTATION 100
Allogeneic Stem Cell Transplant 100
Autologous Stem Cell Transplant 100
CHEMOTHERAPY 100
Types of Chemotherapy for Leukemia 100
Chemotherapy for Acute Leukemias 101
Chemotherapy for Chronic Leukemias 101
TABLE 57 CHEMOTHERAPY DRUGS FOR CML 101
TABLE 58 CHEMOTHERAPY DRUGS FOR CLL 101
Intrathecal Chemotherapy 102
TARGETED DRUG THERAPY FOR LEUKEMIA 102
TABLE 59 TARGETED THERAPY DRUGS 102
MONOCLONAL ANTIBODY THERAPY 102
RADIOIMMUNOTHERAPY 103
TABLE 60 ADVANTAGES OF RADIOIMMUNOTHERAPY 103
RADIATION THERAPY 103
TABLE 61 COMMON RADIATION TREATMENTS: LEUKEMIA 104
EXTERNAL BEAM RADIATION THERAPY (EBRT) 104
TOTAL BODY IRRADIATION 104
TOTAL MARROW IRRADIATION 104
NUTRITION THERAPY AFTER A STEM CELL TRANSPLANT 105
MANAGING SIDE EFFECTS WITH NATUROPATHIC THERAPIES 105
PAIN MANAGEMENT FOR LEUKEMIA 105
TABLE 62 PAIN MEDICATIONS 105
TABLE 63 EMERGING THERAPIES FOR LEUKEMIA 106
CONCLUSIONS 107
CHAPTER 6 HEMATOLOGICAL CANCERS: LYMPHOMA 109
OVERVIEW 109
LYMPHOMA CAUSES 110
TABLE 64 CAUSES FOR LYMPHOMA 111
CLASSIFICATION 111
TABLE 65 LYMPHOMA TYPES 112
STAGING 113
TABLE 66 STAGING FOR HL AND NHL TUMORS 114
NON-HODGKIN LYMPHOMA 114
TABLE 67 MATURE B-CELL NEOPLASMS 115
TABLE 68 MATURE T-CELL AND NATURAL KILLER (NK) CELL NEOPLASMS 115
TABLE 69 HODGKIN LYMPHOMA 116
TABLE 70 IMMUNODEFICIENCY-ASSOCIATED LYMPHO- PROLIFERATIVE
DISORDERS 116
Signs and Symptoms 116
TABLE 71 SYMPTOMS OF LYMPHOMA 117
TABLE 72 FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS (%) 117
Diagnosis and Tests 118
Biopsy 118
Imaging Studies 118
TABLE 73 IMAGING TESTS 118
Bone Marrow Examination 118
Other Tests 119
Lumbar Puncture 119
Organ Function Tests 119
Prognostic Factors 119
TABLE 74 HL, THE INTERNATIONAL PROGNOSTIC INDEX 119
TABLE 75 THE INTERNATIONAL PROGNOSTIC INDEX FOR NHL 120
Lymphoma Treatment 120
Radiation and Chemotherapy 121
Radiation Therapy 121
Chemotherapy 121
Biological Therapy 122
TABLE 76 PROMISING THERAPIES FOR TREATING LYMPHOMA 122
Complementary/Alternative Therapies 122
CHAPTER 7 HEMATOLOGICAL CANCERS: MYELOMA 125
OVERVIEW 125
CAUSE 126
SYMPTOMS 126
COMPLICATIONS OF MYELOMA 126
CRYOGLOBULINEMIA 126
AMYLOIDOSIS 127
TYPES OF MYELOMA 127
INCIDENCE 127
DIAGNOSIS 128
TESTS 128
PROGNOSTIC INDICATORS 129
TABLE 77 PROGNOSTIC INDICATORS FOR MYELOMA 129
BONE MARROW EXAMINATION 130
TABLE 78 OTHER BONE MARROW TESTS 130
STAGING 131
MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE 131
SMOLDERING MULTIPLE MYELOMA 131
INDOLENT MULTIPLE MYELOMA 131
SYMPTOMATIC MULTIPLE MYELOMA 132
TABLE 79 MYELOMA: STAGING CRITERIA 132
TREATMENT AND PROGNOSIS 132
TABLE 80 MYELOMA'S RESPONSE TO TREATMENT 133
Myeloma Therapy 133
Chemotherapy 134
Radiation Therapy 134
Stem Cell Transplantation 134
Supportive Care 135
TABLE 81 SUPPORTIVE CARE 135
OTHER DRUG THERAPY 136
New Drug Therapy 136
TABLE 82 DRUGS FOR MULTIPLE MYELOMA 137
TABLE 83 EMERGING THERAPIES FOR MYELOMA 138
CONCLUSIONS 138
CHAPTER 8 HEMATOLOGICAL CANCER: MYELODYSPLASTIC SYNDROMES 140
TABLE 84 CHARACTERISTICS OF MDS 140
TABLE 85 MDS CAUSES 141
TABLE 86 MDS OR AML: THREE CATEGORIES 142
CLASSES 142
TABLE 87 MYELODYSPLASTIC SYNDROMES: KEY FACTS 142
TABLE 88 FAB CLASSIFICATION OF MDS 143
TABLE 89 THE 2008 WHO CLASSIFICATION OF MDS 144
INTERNATIONAL PROGNOSTIC SCORING SYSTEM 145
TABLE 90 INTERNATIONAL PROGNOSTIC SCORING SYSTEM RISK GROUPS
AND PROGNOSIS 145
DIAGNOSIS AND TESTS 145
TABLE 91 CHANGES IN CELLS AND MDS 146
PROGNOSIS AND TREATMENT OPTIONS 146
CHEMOTHERAPY 147
SUPPORTIVE CARE 147
DRUG PROFILES 149
EPOETIN ALFA (PROCRIT, EPOGEN) 149
DARBEPOETIN (ARANESP) 149
SARGRAMOSTIM (LEUKINE) 150
FILGRASTIM (NEUPOGEN) 150
DECITABINE (DACOGEN) 150
LENALIDOMIDE (REVLIMID) 150
AZACITIDINE 150
PREVIOUSLY TREATED MYELODYSPLASTIC SYNDROMES 151
CONCLUSIONS 151
CHAPTER 9 HEMATOLOGICAL CANCERS: MYELOPROLIFERATIVE DISORDERS 153
TYPES OF CHRONIC MYELOPROLIFERATIVE DISORDERS 153
TABLE 92 CHRONIC MYELOPROLIFERATIVE DISORDERS 153
CLASSIFICATION: WHO 154
TABLE 93 CLASSIFICATION OF MYELOID NEOPLASMS ACCORDING TO THE
2008 WHO CLASSIFICATION SCHEME 155
TABLE 94 MYELOPROLIFERATIVE NEOPLASMS: KEY FACTS 156
STAGES OF CHRONIC MYELOPROLIFERATIVE DISORDERS 156
DIAGNOSIS 157
Tests 157
TABLE 95 DIAGNOSTIC TESTS 157
TREATMENT 157
OTHER DRUG THERAPY 157
POLYCYTHEMIA VERA 158
OVERVIEW 158
TABLE 96 SYMPTOMS OF POLYCYTHEMIA VERA 159
CAUSES 159
RISK FACTORS 159
TABLE 97 BLOOD TESTS FOR POLYCYTHEMIA VERA 160
TREATMENT OF POLYCYTHEMIA VERA 160
DRUGS FOR TREATING POLYCYTHEMIA VERA 160
TABLE 98 TREATMENT FOR POLYCYTHEMIA VERA 161
PROGNOSIS 161
COMPLICATIONS 161
Blood Clots 161
Enlarged Spleen (Splenomegaly) 161
Problems Due to High Levels of Red Blood Cells 162
Other Blood Disorders 162
CHRONIC IDIOPATHIC MYELOFIBROSIS 162
CAUSES 162
TABLE 99 CAUSATIVE FACTORS FOR MYELOFIBROSIS 163
TABLE 100 COMPLICATIONS FROM MYELOFIBROSIS 163
PATHOGENESIS 164
WHO DIAGNOSTIC CRITERIA 164
TABLE 101 WHO DIAGNOSTIC CRITERIA FOR PMF 165
PROGNOSIS 165
TABLE 102 RISK FACTORS 166
SYMPTOMS 166
TABLE 103 IDIOPATHIC MYELOFIBROSIS AND SYMPTOMS 167
TABLE 104 PROGNOSIS 167
TREATMENTS FOR MYELOFIBROSIS 168
TABLE 105 TREATMENT OF CHRONIC IDIOPATHIC MYELOFIBROSIS 169
EXPERIMENTAL DRUG THERAPY 170
Pomalidomide 170
TABLE 106 SOMATIC MUTATIONS 170
ESSENTIAL THROMBOCYTHEMIA 171
TABLE 107 CAUSES OF THROMBOCYTOSIS 171
SYMPTOMS 172
TABLE 108 SYMPTOMS 172
PATHOPHYSIOLOGY 172
DIAGNOSTIC CRITERIA 173
TABLE 109 ESSENTIAL THROMBOCYTHEMIA: DIAGNOSTIC CRITERIA 173
THERAPEUTIC STRATEGIES 174
PROGNOSIS 174
CAUSES, INCIDENCE AND RISK FACTORS 174
GENES: ESSENTIAL THROMBOCYTHEMIA 174
TREATMENT OF ESSENTIAL THROMBOCYTHEMIA 175
DIAGNOSIS 175
TABLE 110 TREATMENT OF ET 176
Anti-platelet Treatment 177
ADP Receptor Antagonists 177
Platelet-Lowering Treatment 177
Anagrelide 178
Interferon-a (IFN-a) 178
ALTERNATIVE CYTOREDUCTIVE THERAPY 178
Pipobroman (PI) 178
Busulfan (BU) 178
JAK2 V617F MUTATION AND MANAGEMENT OF ET 179
CHRONIC NEUTROPHILIC LEUKEMIA 179
TREATMENT 179
TABLE 111 TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA 180
CHRONIC EOSINOPHILIC LEUKEMIA 180
TABLE 112 CHRONIC EOSINOPHILIC LEUKEMIA: SYMPTOMS 180
TREATMENT 180
TABLE 113 TREATMENT OF CHRONIC EOSINOPHILIC LEUKEMIA 181
PIPELINE DRUGS 181
Incyte 181
Jakavi in Europe 182
SUMMARY 182
TABLE 114 CURRENT DRUGS 183
CHAPTER 10 WORLDWIDE INCIDENCE: BLOOD DISORDERS AND BLOOD
CANCER 185
TABLE 115 CANCER KEY FACTS 185
TABLE 116 INCREASE IN CANCER BURDEN: FACTORS 186
INDIA 187
TABLE 117 CANCER CASES AND TREATMENT COST IN INDIA, 2008-2010 ($
MILLIONS) 188
KENYA 188
WORLDWIDE INCIDENCE OF BLOOD CANCER 189
TABLE 118 WORLDWIDE INCIDENCE OF BLOOD CANCER, 2008 (IN
THOUSANDS) 189
TABLE 119 WORLDWIDE INCIDENCE OF BLOOD CANCER IN MEN, 2008
(THOUSANDS) 189
TABLE 120 WORLDWIDE INCIDENCE OF BLOOD CANCER IN WOMEN, 2008
(THOUSANDS) 190
TABLE 121 TOP 10 COUNTRIES' CANCER RATES (PER 100,000) 190
BLOOD CANCER INCIDENCE IN UNITED STATES 191
TABLE 122 ESTIMATED INCIDENCE RATES FOR BLOOD CANCERS IN THE
U.S., 2010 AND 2011 (PER 100,000 POPULATION) 191
FIGURE 1 ESTIMATED INCIDENCE RATES FOR BLOOD CANCERS IN THE
U.S., 2010 AND 2011 (PER 100,000 POPULATION) 191
TABLE 123 ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND
MYELOMA IN THE U.S., 2011 192
FIGURE 2 ESTIMATED NEW CASES OF LEUKEMIA, LYMPHOMA AND
MYELOMA IN THE U.S., 2011 192
TABLE 124 ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE IN THE
U.S., 2012 193
FIGURE 3 ESTIMATED LEUKEMIA AND LYMPHOMA INCIDENCE IN THE U.S.,
2012 193
Deaths 193
LEUKEMIA 194
Reactors and Blood Cancers 194
Signs and Symptoms 195
Leukemia: Worldwide Incidence 196
TABLE 125 GLOBAL INCIDENCE OF LEUKEMIA, 2010 (PER 100,000
INDIVIDUALS) 196
Leukemia in United States 197
TABLE 126 LEUKEMIA INCIDENCE IN THE U.S. 197
TABLE 127 ESTIMATED NEW CASES OF LEUKEMIA IN THE U.S., 2010-2012
(NO. OF CASES) 198
FIGURE 4 ESTIMATED NEW CASES OF LEUKEMIA IN THE U.S., 2010-2012
(NO. OF CASES) 198
TABLE 128 ESTIMATED NEW CASES OF LEUKEMIA IN THE U.S., ADULTS AND
CHILDREN, 2011 (%/NO. OF CASES) 198
TABLE 129 APPROXIMATE PREVALENCE OF DIFFERENT TYPES OF
LEUKEMIA IN THE U.S., 2008 (NO. OF CASES) 199
FIGURE 5 APPROXIMATE PREVALENCE OF DIFFERENT TYPES OF LEUKEMIA
IN THE UNITED STATES, 2008 (NO. OF CASES) 199
Leukemia in Children in the U.S. 200
TABLE 130 LEUKEMIA IN ADULTS AND CHILDREN IN THE U.S., 2011 (NO. OF
CASES) 200
FIGURE 6 LEUKEMIA IN ADULTS AND CHILDREN IN THE U.S., 2011 (NO. OF
CASES) 200
Leukemia Incidence in Adolescents and Young Adults in the
U.S. 201
Leukemia Incidence in Adults in the U.S. 201
TABLE 131 TYPES OF LEUKEMIA IN ADULTS IN THE U.S. 201
TABLE 132 ESTIMATED LEUKEMIA INCIDENCE IN THE U.S., 2012 (NO OF
CASES) 202
FIGURE 7 ESTIMATED LEUKEMIA INCIDENCE IN THE U.S., 2012 (NO. OF
CASES) 202
TABLE 133 INCIDENCE RATES BY RACE, 2005-2009 (PER 100,000 PERSONS) 202
Survival 203
TABLE 134 THE FIVE-YEAR RELATIVE SURVIVAL RATES, 2001-2007 203
TABLE 135 ESTIMATED DEATHS FOR LEUKEMIA IN THE U.S., 2011 204
FIGURE 8 ESTIMATED DEATHS FOR LEUKEMIA IN THE U.S., 2011 204
Leukemia Incidence in the United Kingdom 205
TABLE 136 LEUKEMIA STATISTICS IN THE U.K.: NUMBER OF NEW CASES,
INCIDENCE RATES BY GENDER PER 100,000 POPULATION, 2008 205
Cause 206
TABLE 137 ACS ESTIMATES FOR ACUTE LYMPHOCYTIC LEUKEMIA (ALL)
INCIDENCE IN THE U.S., 2012 207
LYMPHOMA 207
NON-HODGKIN'S LYMPHOMA 207
Signs and Symptoms 208
Possible Causes 208
Treatment 209
Worldwide Incidence 209
TABLE 138 ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS:
WORLDWIDE, 2008 (INCIDENCE RATES PER 100,000 POPULATION) 210
FIGURE 9 ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: WORLDWIDE,
2008 (INCIDENCE RATES PER 100,000 POPULATION) 211
TABLE 139 ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS:
WORLDWIDE, 2008 (MORTALITY RATES PER 100,000 POPULATION) 211
FIGURE 10 ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS:
WORLDWIDE, 2008 (MORTALITY RATES PER 100,000 POPULATION) 212
HODGKIN'S LYMPHOMA 213
TABLE 140 HODGKIN LYMPHOMA WORLDWIDE, 2008 (ESTIMATED
INCIDENCE RATES PER 100,000 POPULATION) 213
FIGURE 11 HODGKIN LYMPHOMA WORLDWIDE, 2008 (ESTIMATED
INCIDENCE RATES PER 100,000 POPULATION) 214
Lymphoma Incidence In Canada 214
Lymphoma and European Union 215
Non-Hodgkin's Lymphoma 215
TABLE 141 ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: EU-27
COUNTRIES, 2008 (AGE-STANDARDIZED INCIDENCE RATES PER 100,000) 215
FIGURE 12 ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: EU-27
COUNTRIES, 2008 (AGE-STANDARDIZED INCIDENCE RATES PER 100,000) 216
TABLE 142 ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: EU-27
COUNTRIES, 2008 (AGE-STANDARDIZED MORTALITY RATES PER 100,000) 217
FIGURE 13 ESTIMATED NON-HODGKIN LYMPHOMA STATISTICS: EU-27
COUNTRIES, 2008 (AGE-STANDARDIZED MORTALITY RATES PER 100,000) 217
Hodgkin's Lymphoma in European Union Countries 218
TABLE 143 HODGKIN LYMPHOMA IN EU-27 COUNTRIES, 2008 (ESTIMATED
INCIDENCE RATES PER 100,000) 219
FIGURE 14 HODGKIN LYMPHOMA IN EU-27 COUNTRIES, 2008 (ESTIMATED
INCIDENCE RATES PER 100,000) 219
United States: Lymphoma 220
New Cases 220
TABLE 144 ESTIMATED NEW CASES AND DEATHS FOR LYMPHOMA IN THE
U.S., 2012 (NO. OF CASES) 221
FIGURE 15 ESTIMATED NEW CASES AND DEATHS FOR LYMPHOMA IN THE
U.S., 2012 (NO. OF CASES) 221
TABLE 145 ESTIMATED NEW CASES AND DEATHS OF LYMPHOMA IN THE
U.S., 2011 AND 2012 (NO. OF CASES) 222
FIGURE 16 ESTIMATED NEW CASES AND DEATHS OF LYMPHOMA IN THE
U.S., 2011 AND 2012 (NO. OF CASES) 222
TABLE 146 ESTIMATED NEW CASES OF LYMPHOMA TYPES IN THE U.S., 2011
AND 2012 (NO. OF CASES) 223
FIGURE 17 ESTIMATED NEW CASES OF LYMPHOMA TYPES IN THE U.S., 2011
AND 2012 (NO. OF CASES) 223
TABLE 147 NEW CASES OF LYMPHOMA BY GENDER, 2011 (NO. OF CASES) 224
FIGURE 18 NEW CASES OF LYMPHOMA BY GENDER, 2011 (NO. OF CASES) 224
TABLE 148 ESTIMATED DEATHS FROM LYMPHOMA BY GENDER, 2011 (NO.
OF CASES) 224
FIGURE 19 ESTIMATED DEATHS FROM LYMPHOMA BY GENDER, 2011 (NO.
OF CASES) 224
TABLE 149 AGE-SPECIFIC INCIDENCE RATES, BY GENDER, FOR NHL 225
TABLE 150 INCIDENCE RATES BY RACE, 2005-2009 (PER 100,000 PEOPLE) 226
TABLE 151 DEATH RATES BY RACE, 2005-2009 (PER 100,000 PEOPLE) 226
Race and Ethnicity 227
Lymphoma in Children 227
Lymphoma in Adolescents and Young Adults 227
Lymphoma in Adults 228
Survival 228
TABLE 152 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY
STAGE AT DIAGNOSIS, 2002-2008 (ALL RACES, BOTH SEXES, %) 229
Lymphoma in United Kingdom 229
TABLE 153 NON-HODGKIN LYMPHOMA IN THE U.K.: NUMBER OF NEW
CASES, INCIDENCE, 2009 (RATES PER 100,000 POPULATION) 229
TABLE 154 NON-HODGKIN LYMPHOMA DEATH IN THE U.K. MORTALITY,
2010 (RATES PER 100,000 POPULATION) 230
Hodgkin Lymphoma in United Kingdom 231
TABLE 155 ESTIMATED HODGKIN LYMPHOMA STATISTICS IN THE U.K., 2008
(NUMBER OF NEW CASES, PER 100,000 POPULATION) 231
TABLE 156 HODGKIN'S LYMPHOMA IN THE U.K., 2008 (ESTIMATED NUMBER
OF DEATHS PER 100,000 POPULATION) 232
FIGURE 20 HODGKIN'S LYMPHOMA IN THE U.K., 2008 (ESTIMATED NUMBER
OF DEATHS PER 100,000 POPULATION) 232
MYELOMA 232
Symptoms 233
Myeloma Incidence Worldwide 233
TABLE 157 MYELOMA INCIDENCE WORLDWIDE, 2008 (ESTIMATED
INCIDENCE RATES PER 100,000 POPULATION) 234
FIGURE 21 MYELOMA INCIDENCE WORLDWIDE, 2008 (ESTIMATED
INCIDENCE RATES PER 100,000 POPULATION) 234
TABLE 158 MYELOMA MORTALITY RATES WORLD WIDE, 2008 (ESTIMATED
INCIDENCE RATES; PER 100,000 POPULATION) 235
FIGURE 22 MYELOMA MORTALITY RATES WORLD WIDE, 2008 (ESTIMATED
INCIDENCE RATES; PER 100,000 POPULATION) 236
Myeloma in European Union Countries 237
TABLE 159 MYELOMA INCIDENCE RATES, EU-27 COUNTRIES, 2008
(ESTIMATED INCIDENCE RATES; PER 100,000 POPULATION) 237
FIGURE 23 MYELOMA INCIDENCE RATES, EU-27 COUNTRIES, 2008
(ESTIMATED INCIDENCE RATES; PER 100,000 POPULATION) 237
TABLE 160 MYELOMA MORTALITY RATES WORLD WIDE, 2008 (ESTIMATED
MORTALITY RATES; PER 100,000 POPULATION) 238
FIGURE 24 MYELOMA MORTALITY RATES, WORLDWIDE, 2008 (ESTIMATED
MORTALITY RATES; PER 100,000 POPULATION) 239
Myeloma in United States 239
TABLE 161 ESTIMATED INCIDENCE AND DEATHS FOR MYELOMA IN THE
U.S., 2011 AND 2012 (NO. OF CASES) 240
FIGURE 25 ESTIMATED INCIDENCE AND DEATHS FOR MYELOMA IN THE
U.S., 2011 AND 2012 (NO. OF CASES) 240
TABLE 162 ESTIMATED INCIDENCE OF MYELOMA IN THE U.S. BY GENDER,
2011 AND 2012 (NO. OF CASES) 241
FIGURE 26 ESTIMATED INCIDENCE OF MYELOMA IN THE U.S. BY GENDER,
2011 AND 2012 (NO. OF CASES) 241
TABLE 163 INCIDENCE RATES BY RACE AND GENDER, 2005-2009 (PER
100,000 PEOPLE) 242
TABLE 164 DEATH RATES BY RACE AND GENDER, 2005-2009 (PER 100,000
PEOPLE) 243
Survival 243
TABLE 165 DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT
DIAGNOSIS, 2002-2008 (ALL RACES, BOTH SEXES, %) 244
Myeloma in the United Kingdom 244
TABLE 166 MYELOMA STATISTICS IN THE U.K. NUMBER OF NEW CASES:
INCIDENCE RATES PER 100,000 POPULATION, 2009 244
TABLE 167 MYELOMA NUMBER OF DEATHS IN THE U.K. MORTALITY RATES
PER 100,000 POPULATION, 2010 245
Conclusions 245
MYELODYSPLASTIC SYNDROMES (MDS) 246
Signs and Symptoms 246
TABLE 168 ESTIMATED NEW CASES FOR MDS IN THE U.S., 2012 247
Race and Ethnicity 248
BLOOD DISEASES AND INCIDENCE 248
ANEMIA 249
SICKLE-CELL ANEMIA 249
THALASSEMIA 250
BLEEDING DISORDERS 251
HEMOPHILIA 251
Worldwide Incidence of Hemophilia 252
Mortality/Morbidity 252
Hemophilia in the United States 253
CLOTTING DISORDERS 253
CHAPTER 11 HEMATOLOGY INSTRUMENTS AND REAGENTS: A GLOBAL
MARKET PERSPECTIVE 256
HEMATOLOGICAL MALIGNANCIES 256
MARKET DYNAMICS: HEMATOLOGY INSTRUMENTS AND REAGENTS 256
TABLE 169 GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET,
THROUGH 2017 ($ MILLIONS) 257
FIGURE 27 GLOBAL HEMATOLOGY INSTRUMENTS AND REAGENTS MARKET,
2010-2017 ($ MILLIONS) 257
GLOBAL MARKET 258
MARKET DRIVERS 258
TABLE 170 KEY PRODUCTS 259
KEY PLAYERS 259
TABLE 171 GLOBAL MAJOR PLAYERS IN THE HEMATOLOGY MARKET 260
KEY COMPANY PROFILES 260
Roche 260
Sysmex 261
Flow Cytometers 261
TABLE 172 FLOW CYTOMETRY 171: KEY PLAYERS 262
TABLE 173 FLOW CYTOMETRY PRODUCTS: SALES AND FORECAST,
THROUGH 2017 ($ MILLIONS) 262
FIGURE 28 FLOW CYTOMETRY PRODUCTS: SALES AND FORECAST,
2010-2017 ($ MILLIONS) 263
TABLE 174 MAJOR FLOW CYTOMETRY APPLICATIONS 263
Coagulation Analyzers 264
TABLE 175 CELL ANALYZERS: KEY PLAYERS 264
Future Outlook 264
Blood Disorder Tests and Market 265
TABLE 176 HEMATOLOGY TESTS 266
HEMATOLOGY TEST PRODUCTS AND MARKET 266
Complete Blood Count (CBC) 266
TABLE 177 COMPLETE BLOOD COUNT: COMPONENTS MEASURED 267
MAJOR ROUTINE AND SPECIAL HEMATOLOGY TESTS 267
Partial Thromboplastin Time 267
Total Serum Protein 268
Chemistry Panel 268
TABLE 178 TESTS INCLUDED IN A CHEMISTRY SCREEN 268
TABLE 179 CHEMISTRY SCREEN 269
Vitamin B12 269
The Cold Agglutinins Test 269
Prothrombin 269
Reticulocyte 270
Urine Cytology 270
TABLE 180 URINE TESTS AND APPLICATIONS 270
BLOOD PROTEIN TESTING 271
TUMOR MARKER TESTS 271
IN VITRO DIAGNOSTIC MARKET 272
TABLE 181 IVD PRODUCTS MARKET: SALES AND FORECAST, THROUGH 2017
($ MILLIONS) 272
FIGURE 29 IVD PRODUCTS MARKET: SALES AND FORECAST, 2010-2017 ($
MILLIONS) 272
TABLE 182 UNITED STATES: IVD MARKET SALES AND FORECAST, THROUGH
2017 ($ MILLIONS) 273
FIGURE 30 UNITED STATES: IVD MARKET SALES AND FORECAST, 2010-2017
($ MILLIONS) 273
Immunoassays 273
TABLE 183 GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS: SALES AND
FORECAST, THROUGH 2017 ($ MILLIONS) 274
FIGURE 31 GLOBAL MARKET FOR IMMUNOASSAY SYSTEMS: SALES AND
FORECAST, 2010-2017 ($ MILLIONS) 274
Market Trends 274
TABLE 184 GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS: SALES
AND FORECAST, THROUGH 2017 ($ MILLIONS) 275
FIGURE 32 GLOBAL MARKET FOR ENZYME IMMUNOASSAY SYSTEMS: SALES
AND FORECAST, 2010-2017 ($ MILLIONS) 275
TABLE 185 KEY PLAYERS IN THE IMMUNOASSAYS MARKET 276
Molecular Diagnostics 276
TABLE 186 MOLECULAR DIAGNOSTICS MARKET: SALES AND FORECAST,
THROUGH 2017 ($ MILLIONS) 277
FIGURE 33 MOLECULAR DIAGNOSTICS MARKET: SALES AND FORECAST,
2010-2017 ($ MILLIONS) 277
TABLE 187 MAJOR PLAYERS: MOLECULAR DIAGNOSTICS MARKET 278
POINT-OF-CARE MARKET 278
TABLE 188 THE POINT-OF-CARE (POC) TESTING MARKET: SALES AND
FORECAST, THROUGH 2017 ($ MILLIONS) 278
FIGURE 34 THE POINT-OF-CARE (POC) TESTING MARKET: SALES AND
FORECAST, 2010-2017 ($ MILLIONS) 278
TABLE 189 GLOBAL MARKET FOR POC TESTS: SALES AND FORECAST,
THROUGH 2017 ($ MILLIONS) 279
FIGURE 35 GLOBAL MARKET FOR POC TESTS: SALES AND FORECAST, 2012
AND 2017 ($ MILLIONS) 280
POC Immunoassays 280
TABLE 190 THE POINT-OF-CARE IMMUNOASSAY MARKET: SALES AND
FORECAST, THROUGH 2017 ($ MILLIONS) 281
FIGURE 36 THE POINT-OF-CARE IMMUNOASSAY MARKET: SALES AND
FORECAST, 2012 AND 2017 ($ MILLIONS) 281
Cardiac Markers 281
POC Market Penetration 282
FUTURE OUTLOOK 282
BLOOD TRANSFUSION DIAGNOSTIC TESTING MARKET 282
TABLE 191 MARKET PLAYERS 283
CONCLUSIONS 283
CHAPTER 12 BLOOD DISEASES TREATMENTS MARKET 285
THERAPEUTIC DRUGS AND MARKET 285
TABLE 192 GLOBAL BLOOD DISORDER MARKET, THROUGH 2017 ($
MILLIONS) 285
FIGURE 37 GLOBAL BLOOD DISORDER MARKET, 2010-2017 ($ MILLIONS) 285
TABLE 193 GLOBAL BLOOD DISORDER MARKET SHARE, 2010 AND 2017 (%) 286
KEY MARKET PLAYERS 287
TABLE 194 PATENT EXPIRIES OF MAJOR BLOCKBUSTERS 287
TABLE 195 KEY PLAYERS: PRODUCTS AND MARKET SHARE, 2010 (%) 287
TABLE 196 MARKET DRIVERS 288
TABLE 197 MARKET RESTRAINTS 288
ANEMIA TREATMENT MARKET 288
TABLE 198 ANEMIA TREATMENT MARKET, THROUGH 2017 ($ MILLIONS) 289
FIGURE 38 ANEMIA TREATMENT MARKET, 2010-2017 ($ MILLIONS) 289
TABLE 199 ERYTHROPOIETIN STIMULATING AGENTS (ESAS) 290
Aranesp 290
TABLE 200 KEY ANEMIA DRUGS SALES, 2010-2012 ($ MILLIONS) 290
FIGURE 39 KEY ANEMIA DRUGS SALES, 2010-2012 ($ MILLIONS) 290
Epogen 291
Procrit 291
Cost 292
NeoRecormon/Epogin 292
TABLE 201 NEORECORMON/EPOGIN SALES AND FORECAST, 2010-2012 ($
MILLIONS) 293
FIGURE 40 NEORECORMON/EPOGIN SALES AND FORECAST, 2010-2012 ($
MILLIONS) 293
TABLE 202 GLOBAL NEORECORMON/EPOGIN SALES, 2009 ($ MILLIONS/%) 294
Competition 294
MEDICARE AND ANEMIA DRUG USAGE 294
Anemia Treatment 294
TABLE 203 COMMON ANEMIA TREATMENTS 295
Anemia Market and New Drugs 295
Market Trends 296
Major Players 296
GlaxoSmithKline and Bayer 296
FibroGen 297
Ligand 298
Pluristem Therapeutics 298
AMAG Pharma 298
Akebia Therapeutics 298
TABLE 204 AKEBIA THERAPEUTICS ANEMIA DRUG IN
DEVELOPMENT-AKB-6548 299
THROMBOSIS TREATMENT MARKET 299
TABLE 205 GLOBAL THROMBOSIS THERAPEUTIC MARKET: SALES AND
FORECAST, THROUGH 2017 ($ MILLIONS) 300
FIGURE 41 GLOBAL THROMBOSIS THERAPEUTIC MARKET: SALES AND
FORECAST, 2010-2017 ($ MILLIONS) 300
TABLE 206 LEADING DRUGS IN THE ANTITHROMBOTIC AGENTS MARKET 301
GLOBAL ANTICOAGULANT MARKET 301
Oral Anticoagulants 302
Injectable Anticoagulants 303
TABLE 207 GLOBAL ANTICOAGULANT DRUG MARKET SALES AND FORECAST,
THROUGH 2017 ($ MILLIONS) 304
FIGURE 42 GLOBAL ANTICOAGULANT DRUG MARKET SALES AND FORECAST,
2010-2017 ($ MILLIONS) 304
Development of New Drugs and Market 304
Antiplatelet Market 305
TABLE 208 GLOBAL ANTIPLATELET DRUG MARKET, THROUGH 2017 ($
MILLIONS) 305
FIGURE 43 GLOBAL ANTIPLATELET DRUG MARKET, 2010-2017 ($ MILLIONS) 305
TABLE 209 ANTIPLATELET AND ANTICOAGULANT DRUGS 306
DRUG PROFILES 306
Plavix 306
Generic Versions of Clopidogrel 307
Plavix: History 307
Plavix: Market Trends 307
Effient/Efient 308
COMPETITION 309
TABLE 210 ANTIPLATELET DRUGS (PLATELET ADP ANTAGONISTS): SALES
AND FORECAST, THROUGH 2017 ($ MILLIONS) 309
TABLE 211 U.S. SALES: PLAVIX, 2012 ($ MILLIONS) 310
Brilinta 310
Edoxaban 310
Semuloparin 311
TABLE 212 GLOBAL SEMULOPARIN SALES AND FORECAST, THROUGH 2017
($ MILLIONS) 311
FIGURE 44 GLOBAL SEMULOPARIN SALES AND FORECAST, 2011-2017 ($
MILLIONS) 312
Enoxaparin 312
Generic Lovenox 312
TABLE 213 ANTITHROMBOTIC AGENTS (BY PHARMACOLOGICAL CLASS):
SALES AND FORECAST, 2010-2017 ($ MILLIONS) 313
Lovenox History 313
NEW DRUGS 314
Xarelto 314
TABLE 214 XARELTO: APPROVALS IN VENOUS ARTERIAL THROMBOEMBOLIC
(VAT) INDICATIONS 316
Pradaxa 317
Arixtra 317
TABLE 215 ANTITHROMBOTIC AGENTS IN DEVELOPMENT 318
Vorapaxar 318
Activase 319
TABLE 216 ACTIVASE: SALES AND FORECAST, THROUGH 2017 ($ MILLIONS) 319
Angiomax 319
TABLE 217 ANGIOMAX: SALES AND FORECAST, 2010-2017 ($ MILLIONS) 320
Market Trends for Anticoagulants 320
Warfarin 320
PLATELET AGGREGATION INHIBITORS AND MARKET IMPACT 321
TABLE 218 KEY PLATELET AGGREGATION INHIBITOR DRUG SALES AND
FORECAST, 2010-2017 ($ MILLIONS) 321
TABLE 219 PLATELET AGGREGATION INHIBITORS: PIPELINE DRUGS 323
Cangrelor 323
TABLE 220 PLATELET INHIBITOR: PIPELINE DRUGS 324
TABLE 221 THROMBOSIS MARKET: PIPELINE DRUGS 325
NEUTROPENIA TREATMENT MARKET 326
TABLE 222 GLOBAL NEUTROPENIA DRUG MARKET: SALES AND FORECAST,
THROUGH 2017 ($ MILLIONS) 327
FIGURE 45 GLOBAL NEUTROPENIA DRUG MARKET: SALES AND FORECAST,
2010-2017 ($ MILLIONS) 327
TABLE 223 KEY DRUGS 327
Neulasta (Pegfilgrastim) and Neupogen (Filgrastim) 328
TABLE 224 GROWTH FACTORS FOR TREATING NEUTROPENIA 329
TABLE 225 WORLDWIDE SALES OF NEULASTA/NEUPOGEN, 2010-2012 ($
MILLIONS) 329
TABLE 226 SARGRAMOSTIM SALES, 2010 ($ MILLIONS) 329
Filgrastim Biosimilars 330
TABLE 227 COMPANIES IN EUROPE WITH SHORT-ACTING FILGRASTIMS IN
PHASE 3 CLINICAL DEVELOPMENT 330
Teva Pharmaceutical 330
Competition in Neutropenia Market 330
HEMOPHILIA MARKET 331
TABLE 228 HEMOPHILIA A THERAPEUTICS MARKET: SALES AND FORECAST,
THROUGH 2017 ($ MILLIONS) 331
FIGURE 46 HEMOPHILIA A THERAPEUTICS MARKET: SALES AND FORECAST,
2010-2017 ($ MILLIONS) 331
TABLE 229 KEY PLAYERS IN THE HEMOPHILIA A THERAPEUTICS MARKET 332
Drugs for the Hemophilia Market 332
TABLE 230 KEY HEMOPHILIA DRUGS 333
TABLE 231 GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS
FOR HEMOPHILIA, 2010 ($ MILLIONS) 333
FIGURE 47 GLOBAL MARKET FOR RECOMBINANT COAGULATION FACTORS
FOR HEMOPHILIA, 2010 ($ MILLIONS) 333
Market Barriers 334
Drug Pipeline 334
Novo Nordisk Halts Development of Hemophilia Drug 335
Competition 335
Baxter 335
Advate 336
Biogen Idec 336
Blood Disorders Pipeline 336
TABLE 232 GLOBAL BLOOD DISORDERS PIPELINE MOLECULES (%) 336
CONCLUSIONS 337
CHAPTER 13 HEMATOLOGICAL CANCER THERAPIES: MARKET 339
OVERVIEW 339
HEMATOLOGICAL CANCERS DRUG MARKET 339
CLASSIFICATION OF HEMATOLOGIC MALIGNANCIES 339
The Chronic Myeloid Disorders 340
CYTOTOXIC THERAPIES MARKET 340
TABLE 233 CYTOTOXIC THERAPIES MARKET INDICATIONS 340
TABLE 234 LIST OF LEUKEMIA MEDICATIONS 341
TABLE 235 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($
MILLIONS) 342
FIGURE 48 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 ($
MILLIONS) 342
TABLE 236 U.S. CYT
To order this report:Pathology Industry: Drugs and Diagnostics for Hematological Disorders: Global Markets
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001
SOURCE Reportlinker
Share this article